The selection of an inappropriate dressing regimen can result in moderate to heavily exuding wounds having a negative impact upon the patient’s skin and quality of life. However, before integrating a new dressing into a wound formulary, the clinician responsible must ascertain the product’s quality and cost-effectiveness through appropriate research. This article features a 50-patient evaluation of Versiva® XC® gelling foam dressing, which combines a foam construction with Hydrofiber® technology in a thin easy-to-use dressing, and its effect on wound-related quality of life in patients with wounds of differing aetiology.